We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis (ReSTORE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03667690
Recruitment Status : Completed
First Posted : September 12, 2018
Results First Posted : January 6, 2023
Last Update Posted : January 6, 2023
Sponsor:
Information provided by (Responsible Party):
Cidara Therapeutics Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by optional oral fluconazole).

Condition or disease Intervention/treatment Phase
Candidemia Mycoses Fungal Infection Invasive Candidiases Drug: Rezafungin for Injection Drug: Caspofungin Drug: Fluconazole Drug: intravenous placebo Drug: oral placebo Phase 3

Detailed Description:
A Phase 3, multicenter, prospective, randomized, double-blind, efficacy and safety study of Rezafungin for Injection versus an active comparator regimen of caspofungin followed by optional oral fluconazole step-down therapy in subjects with candidemia and/or invasive candidiasis.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 199 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection vs. Intravenous Caspofungin Followed by Oral Fluconazole Step Down in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis
Actual Study Start Date : October 7, 2018
Actual Primary Completion Date : October 7, 2021
Actual Study Completion Date : October 7, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Yeast Infections

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Group 1: Rezafungin for Injection

Subjects in Rezafungin treatment group will receive a 400 mg loading dose in Week 1, followed by 200 mg once weekly, for a total of 2 to 4 doses.

Daily intravenous placebo infusions, when not administered Rezafungin and a daily placebo for oral step-down therapy (first eligibility on Day 4 or later as advised by a site's national/regional/local guidelines) administered every day.

 Drug: Rezafungin for Injection
Intravenous antifungal therapy

Drug: oral placebo
Microcrystalline cellulose
Other Name: encapsulated cellulose
Active Comparator: Group 2: Caspofungin

Subjects in caspofungin arm will receive a total treatment of ≥14 days beginning with a single caspofungin 70 mg IV loading dose on Day 1 followed by 50 mg IV once daily up to 28 days. After ≥3 days of caspofungin treatment(or the minimum duration of IV therapy advised by the site's national/regional/local guidelines, whichever is greater), subjects may be switched to oral fluconazole if specific parameters are met.

If the subject qualifies, then oral step-down therapy of fluconazole (6 mg/kg to the nearest 200 mg) is administered. After switch to oral step down before Day 8, subjects in the caspofungin group will receive IV placebo on Day 8 to preserve the study blind.

 Drug: Caspofungin
Intravenous antifungal therapy
Other Name: Cancidas

Drug: Fluconazole
Oral antifungal therapy
Other Name: generic fluconazole

Drug: intravenous placebo
Normal saline
Other Name: placebo infusion


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. All-Cause Mortality (US FDA Only) [ Time Frame: Day 30 (-2 days) ]
    The number and percentage of subjects in each treatment group who are alive and deceased (or with missing data) in the mITT population.

  2. Global Response as Assessed by Data Review Committee (EU European Medicines Agency [EMA] Only) [ Time Frame: Day 14 (±1 day) ]
    The number and percentage of subjects in each treatment group who have a global response of cure (clinical cure as assessed by the Investigator, radiological cure [for qualifying invasive candidiasis subjects at baseline], and mycological eradication, as confirmed by the Data Review Committee [DRC]), failure and indeterminate in the mITT population. A global response of cure is indicative of an efficacious outcome and the desired result, whereas a response of failure is indicative of a non-efficacious outcome and the undesired response. Indeterminate responses indicate there was not enough data obtained to determine if the response was cure or failure. Definitions for the global responses of cure, failure, and indeterminate are complex. Detailed definitions for the possible responses to this outcome measure type are provided in Table 7 (Global Response) of the clinical protocol.


Secondary Outcome Measures :
  1. Global Response as Assessed by Data Review Committee (US FDA Only) [ Time Frame: Day 14 (±1 day) ]
    The number and percentage of subjects in each treatment group who have a global response of cure (clinical cure as assessed by the Investigator, radiological cure [for qualifying invasive candidiasis subjects at baseline], and mycological eradication, as confirmed by the Data Review Committee [DRC]), failure and indeterminate in the mITT population. A global response of cure is indicative of an efficacious outcome and the desired result, whereas a response of failure is indicative of a non-efficacious outcome and the undesired response. Indeterminate responses indicate there was not enough data obtained to determine if the response was cure or failure. Definitions for the global responses of cure, failure, and indeterminate are complex. Detailed definitions for the possible responses to this outcome measure type are provided in Table 7 (Global Response) of the clinical protocol.

  2. All-Cause Mortality (EU EMA Only) [ Time Frame: Day 30 (-2 days) ]
    The number and percentage of subjects in each treatment group who are alive and deceased (or with missing data) in the mITT population.

  3. Comparison of Global Response (as Assessed by the DRC) by Visit [ Time Frame: Day 5, Day 30 (-2 days), End of Treatment (EOT) (≤2 days of last dose) and Follow-up (Days 52-59) ]
    The number and percentage of subjects in each treatment group who have a global response of cure (clinical cure as assessed by the Investigator, radiological cure [for qualifying invasive candidiasis subjects at baseline], and mycological eradication, as confirmed by the Data Review Committee [DRC]), failure and indeterminate in the mITT population. A global response of cure is indicative of an efficacious outcome and the desired result, whereas a response of failure is indicative of a non-efficacious outcome and the undesired response. Indeterminate responses indicate there was not enough data obtained to determine if the response was cure or failure. Definitions for the global responses of cure, failure, and indeterminate are complex. Detailed definitions for the possible responses to this outcome measure type are provided in Table 7 (Global Response) of the clinical protocol.

  4. Comparison of Mycological Eradication by Visit [ Time Frame: Day 5, Day 14 (±1 day), Day 30 (-2 days), End of Treatment (EOT) (≤2 days of last dose), and Follow-up (Days 52-59) ]

    The number and percentage of subjects in each treatment group who have a mycological response of eradication, failure, or indeterminate in the mITT population. A mycological response of eradication means clearance of objective evidence of infection and is indicative of an efficacious outcome and the desired result, whereas a response of failure is indicative of a non-efficacious outcome and the undesired response. Indeterminate responses indicate there was not enough data obtained to determine if the response was eradication or failure. Definitions for the mycological responses of eradication, failure, and indeterminate are complex. Detailed definitions for the possible responses to this outcome measure type are provided in Table 8 (Mycological Response) of the clinical protocol.

    Note: Eradication includes both documented and presumed eradication.


  5. Comparison of Investigators' Assessment of Clinical Response by Visit [ Time Frame: Day 5, Day 14 (±1 day), Day 30 (-2 days), End of Treatment (EOT) (≤2 days of last dose), and Follow-up (Days 52-59) ]
    The number and percentage of subjects in each treatment group for whom the Investigator determined a clinical response of cure, failure, or indeterminate in the mITT population. A clinical response of cure, as assessed by the Investigator, is indicative of an efficacious outcome and the desired result, whereas a response of failure is indicative of a non-efficacious outcome and the undesired response. Indeterminate responses indicate there was not enough data obtained to determine if the response was cure or failure. Definitions for the clinical responses of cure, failure, and indeterminate are complex. Detailed definitions for the possible responses to this outcome measure type are provided in Table 9 (Investigator's Assessment of Clinical Response) of the clinical protocol.

  6. Comparison of Radiological Response by Investigator by Visit [ Time Frame: Day 5, Day 14 (±1 day), Day 30 (-2 days), End of Treatment (EOT) (≤2 days of last dose), and Follow-up (Days 52-59) ]
    The number and percentage of subjects with invasive candidiasis (documented by radiologic/imaging evidence at baseline) in each treatment group who have a radiological response (as assessed by the Investigator) of cure, failure, and indeterminate in the mITT population. A radiological response of cure is indicative of an efficacious outcome and the desired result, whereas a response of failure is indicative of a non-efficacious outcome and the undesired response. Indeterminate responses indicate there was not enough data obtained to determine if the response was cure or failure. Definitions for the radiological responses of cure, failure, and indeterminate are complex. Detailed definitions for the possible responses to this outcome measure type are provided in Table 10 (Radiological Response) of the clinical protocol.

  7. Number of Subjects With Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: Day 1 through Follow-up Visit (Days 52-59) ]

    The number and percentage of subjects in each treatment group that experienced at least one treatment-emergent adverse event (TEAE) based on clinical chemistry, hematology and urine analysis laboratory test, vital sign, physical exams and electrocardiogram (ECG) abnormalities.

    Notes: A subject with multiple adverse events (AEs) was counted only once. TEAE was defined as an AE that occurred during or after study drug administration and up through the Follow-up visit. The maximum severity and strongest relationship were counted for subjects with multiple events.


  8. Evaluate Pharmacokinetics (Cmax) [ Time Frame: Day 1, 10 minutes before the end of infusion ]
    Evaluate the maximum plasma concentration (Cmax) of rezafungin for injection.

  9. Evaluate Pharmacokinetics (Cmin) [ Time Frame: Day 8, pre-dose, within 30 minutes prior to the start of infusion ]
    Evaluate the minimum plasma concentration (Cmin) of rezafungin for injection.

  10. Evaluate Pharmacokinetics (Cmin) [ Time Frame: Day 15, pre-dose, within 30 minutes prior to the start of infusion ]
    Evaluate the minimum plasma concentration (Cmin) of rezafungin for injection.

  11. Evaluate Pharmacokinetics (Cmin) [ Time Frame: Day 22, pre-dose, within 30 minutes prior to the start of infusion ]
    Evaluate the minimum plasma concentration (Cmin) of rezafungin for injection.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Willing and able to provide written informed consent. If the subject is unable to consent for himself/herself, a legally acceptable representative must provide informed consent on his/her behalf.
  2. Males or females ≥18 years of age.

  3. Established mycological diagnosis of candidemia and/or invasive candidiasis from a sample taken ≤4 days (96 hours) before randomization defined as

    • ≥1 blood culture positive for yeast or Candida OR
    • Positive test for Candida from a Sponsor-approved rapid in vitro diagnostic (IVD) OR
    • Positive gram stain (or other method of direct microscopy) for yeast or positive culture for Candida spp. from a specimen obtained from a normally sterile site.
  4. Presence of one or more systemic signs attributable to candidemia or invasive candidiasis appearing from ≤12 hours prior to the qualifying positive culture through time of randomization.
  5. Willing to initiate or continue medical treatment to cure infections, including receipt of antibiotics and surgical procedures, if required.
  6. Female subjects of childbearing potential (all female subjects between 18 years <2 years post-menopausal unless surgically sterile) must agree to and comply with using one barrier method (e.g., female condom with spermicide) plus one other highly effective method of birth control, or sexual abstinence while participating in this study. Male subjects must be vasectomized, abstain from sexual intercourse, or agree to use barrier contraception, and also agree not to donate sperm while participating in the study and for 90 days thereafter (and at least 120 days from the last dose of study drug).
  7. For Candidemia only subjects, drawing of a set of blood cultures within 12 hours prior to randomization in the study. The result of these blood cultures is not required for inclusion in the study.

Exclusion Criteria:

  1. Any of the following forms of invasive candidiasis at baseline:

    1. Septic arthritis in a prosthetic joint (septic arthritis in a native joint is allowed)
    2. Osteomyelitis
    3. Endocarditis or myocarditis
    4. Meningitis, endophthalmitis, chorioretinitis, or any central nervous system infection
    5. Chronic disseminated candidiasis
    6. Urinary tract candidiasis due to ascending Candida infection secondary to obstruction or surgical instrumentation of the urinary tract

  2. Received systemic treatment with an antifungal agent at approved doses for treatment of candidemia for >48 hours (e.g., >2 doses of a once daily antifungal agent or >4 doses of a twice daily antifungal agent) ≤4 days (96 hours) before randomization

    a. Exception: Receipt of antifungal therapy to which any Candida spp. isolated in culture is not susceptible

  3. Alanine aminotransferase or aspartate aminotransferase levels >10-fold the upper limit of normal
  4. Severe hepatic impairment in subjects with a history of chronic cirrhosis (Child-Pugh score >9)
  5. Presence of an indwelling vascular catheter or device that cannot be removed or an abscess that cannot be drained and is likely to be the source of candidemia or invasive candidiasis
  6. Known hypersensitivity to Rezafungin for Injection, caspofungin, any echinocandin, or to any of their excipients
  7. Meets National Cancer Institute Common Terminology Criteria for Adverse Events, version 5, criteria for ataxia, tremor, motor neuropathy, or sensory neuropathy of Grade 2 or higher
  8. History of severe ataxia, tremor, or neuropathy or a diagnosis of multiple sclerosis or a movement disorder (including Parkinson's Disease or Huntington's Disease)
  9. Planned or ongoing therapy at Screening with a known neurotoxic medication
  10. Previous participation in this or any previous rezafungin study
  11. Current participation in another interventional treatment trial with an investigational agent
  12. Recent use of an investigational medicinal product within 28 days of the first dose of study drug or presence of an investigational device at the time of screening.
  13. Pregnant or lactating females
  14. The Principal Investigator (PI) is of the opinion the subject should not participate in the study
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03667690


Locations
Show Show 132 study locations
Sponsors and Collaborators
Cidara Therapeutics Inc.
Investigators
Layout table for investigator information
Study Director: Taylor Sandison, MD, MPH Cidara Therapeutics Inc.
  Study Documents (Full-Text)

Documents provided by Cidara Therapeutics Inc.:
Study Protocol  [PDF] October 15, 2020
Statistical Analysis Plan  [PDF] November 22, 2021

More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Cidara Therapeutics Inc.
ClinicalTrials.gov Identifier: NCT03667690    
Other Study ID Numbers: CD101.IV.3.05
First Posted: September 12, 2018    Key Record Dates
Results First Posted: January 6, 2023
Last Update Posted: January 6, 2023
Last Verified: December 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Cidara Therapeutics Inc.:
Mycoses
Candidiasis
Candidiasis, Invasive
Candidemia
Fungemia
Sepsis
Invasive Fungal Infections
Systemic Inflammatory Response Syndrome
Pathologic Processes
Fluconazole
Caspofungin
 Echinocandins
Antifungal Agents
Anti-infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Physiological Effects of Drugs
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 CYP2C19 Inhibitors
Additional relevant MeSH terms:
Layout table for MeSH terms
Mycoses
Candidiasis
Candidemia
Candidiasis, Invasive
Infections
Bacterial Infections and Mycoses
Invasive Fungal Infections
Fungemia
Sepsis
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes
Fluconazole
Caspofungin
 Rezafungin
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 CYP2C19 Inhibitors